![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 22014-22019, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, April 4, 2000
The systemic response to endotoxin is
characterized by hypotension and severe reductions in blood pressure,
leading to cardiovascular collapse that can accompany septicemia. The
renin/angiotensin system would normally be expected to respond to
hypotensive challenge; however, inflammation appears to modify this
response. This study identifies a strong acute phase response of the
kidney that is characterized by enhanced expression of serum amyloid A,
haptoglobin and tissue inhibitor for metalloproteinase-1 and a reduced
expression of renin. Equivalent regulatory effects were observed for
the immortalized As4.1 kidney cell line that models certain features of
juxtaglomerular cells. Oncostatin M, a known endotoxin-responsive proinflammatory cytokine, proved to be an effective inhibitor of renin
gene expression. Suppression by oncostatin M involves activated STAT5
and requires an inhibitory element in the renin promoter that functions
separately from cell type-specific enhancer elements. The renal acute
phase reaction, unlike the liver acute phase reaction, is more strongly
dependent on locally produced inflammatory factors.
Tissue damage, infection, or endotoxin induces a local
inflammatory reaction by the recruitment of an interacting network of
effector cells and intercellular mediators (1). The various cells
respond through panels of inflammatory factors, which on one side
augment the local response and, on the other side, enter circulation
causing systemic propagation of the acute phase reaction. The liver
response, in particular, stands out through the massive changes in
acute phase plasma proteins. The local inflammatory response invariably
affects endothelial cells, which in part through NO-mediated mechanisms
effect relaxation of adjacent smooth muscle (2, 3). Vasodilation in
turn assists in plasma effusion and extravasation of chemotactically
mobilized leukocytes. The accompanying drop in blood pressure should
serve generally as a signal for compensatory reaction to restore normal
vascular tone by mobilization of the renin/angiotensin system. Although inflammatory conditions have consistently been noted to elevate angiotensinogen mRNA levels in liver (4) and angiotensinogen levels
in plasma in parallel with the induction of acute phase proteins
(APP)1 (5, 6), plasma renin
concentration and plasma renin activity have been noted to exhibit
complex and variable kinetic alterations (7, 8), and increases in renin
expression have not been reported. In this study we identify a kidney
response to endotoxin and systemic inflammatory mediators that involves
an enhanced expression of plasma proteins generally associated with the
liver acute phase reaction and a reduced expression of renin. The
suppression of renin is contrasted by an induction of renal serum
amyloid A (SAA), haptoglobin, and TIMP-1.
Reporter Gene Constructs and Expression Vectors--
The CAT
reporter gene constructs were: the STAT3- and STAT5-sensitive
p(8xHRRE)-CAT (9) and pTIMP-1-CAT (containing TIMP-1 promoter region
Cell Transfection and Analysis--
As4.1 cells (American Type
Culture Collection CRL 2193) were maintained in Dulbecco's modified
Eagle's medium containing 10% fetal calf serum and antibiotica.
Transfections were carried out with FuGene6 (4 µg of DNA and 6 µl
of FuGene6) according to the manufacturer's recommendation (Roche
Molecular Biochemicals). All transfections included 0.25 µg of
pEGFP-N1 as marker, 3 µg of CAT reporter construct, and 0-0.75 µg
of expression vector for transcription factors. Transfected cultures
were passaged, and subcultures were treated in serum free Dulbecco's
modified Eagle's medium containing 0-100 ng/ml of recombinant human
IL-6 (Genetics Institute), LIF (Immunex Corp), epidermal growth factor (Collaborative Research), growth hormone (Genentech), mouse OSM (produced by transiently transfected COS cells; Ref. 16), 10 ng/ml
IL-1 Inflammatory Reactions in Mice and RNA Analysis--
Adult
(10-12 weeks old) male and female C57BL/6 mice received either two
subdermal injections of 25 µl of turpentine on both flanks of the
hind legs (sterile tissue injury model) or a single intraperitoneal
injection of 50 µg of LPS in 100 µl of phosphate-buffered saline/25
g of body weight (endotoxemia model). Each experimental series included
2-5 replicate animals/treatment. Treatment with phosphate-buffered
saline alone served as control. To activate an OSM-specific systemic
reaction, mice received an intraperitoneal injection of 0.5 ml of
phosphate-buffered saline containing 2 × 107
plaque-forming units of the adenovirus with deletion of the early regions 1 and 3 region (17) and insertion of the cDNA for murine OSM under the control of the murine cytomegalovirus promoter/enhancer, AdmOSM (18), or of the control virus, Addl70-3. RNAs were extracted from liver and kidney by the Trizol method (Life Technologies, Inc.).
Aliquots of 5-20 µg of total RNA were separated on a formaldehyde containing agarose gel, transferred to nitrocellulose, and reacted with
32P-labeled cDNAs to mouse renin, haptoglobin, SAA-3 or
SAA-1, Two separate mouse models of in vivo inflammatory
reactions were examined for effects on kidney. One model, the
LPS-initiated intraperitoneal inflammation model, couples a systemic
distribution of LPS and activation of endotoxin-responsive cells at
different organ sites (19, 20) to produce inflammatory cytokines,
including IL-1 Within 24 h following LPS administration, the characteristic
induction of the representative APPs, haptoglobin and SAA, was observed
for liver (Fig. 1A,
bottom panel). Analysis of kidney RNA showed an appreciable
induction of the same two plasma proteins, although the peak values
observed were a fraction of those found for liver. The kidney RNA
analysis also revealed a 2-3-fold LPS-mediated reduction of renin
mRNA (Fig. 1, A, top panel, and B,
left panel), which appeared to be inversely correlated with
the prominent induction of TIMP-1 and SAA.
A quantitatively distinct pattern of regulation was evident in animals
undergoing turpentine-elicited tissue injury. It was more effective in
inducing APP genes in the liver and of SAA and haptoglobin in the
kidney but produced only a minor induction of TIMP-1 (Fig.
1A) and somewhat lower suppression of renin than LPS
treatment (Fig. 1B, left panel). The more
prominent effects of turpentine induction on liver and kidney APP genes
was attributed to systemically distributed cytokines, of which IL-6 is
probably a major component (24, 25). The LPS-specific activity was attributed to both systemically distributed (26) and locally elicited
production of inflammatory mediators that act on cells in the same
tissue context. The particularly effective induction of TIMP-1 and
reduction of renin may represent the effects of LPS-dependent renal mediators.
To profile the effects of specific factors on renal gene regulation, we
turned to the As4.1 murine kidney cell line that exhibits features
characteristic of juxtaglomerular cells, such as prominent renin
expression (27). These cells were treated with cytokines predicted to
be induced by LPS, namely OSM, IL-6, LIF, IL-1 The combination of OSM with IL-1 As4.1 cells offered the opportunity to identify the signal transduction
pathways utilized. Short term treatment with a panel of cytokines
indicated a most active OSM response system recognized by the
relatively high levels of phosphorylated STAT3, STAT5, and ERKs (Fig.
2A). The IL-6 response
exhibited a strong STAT3 activation but lower effects on STAT5 and ERK.
The low LIF responsiveness of As4.1 cells was confirmed. The signaling
pattern of IL-6 cytokines as regards the relative involvement of STAT
and ERK pathways was contrasted by the action of EGF and growth
hormone, which primarily affected ERK and STAT5, respectively (Fig.
2A). IL-6 and OSM elicited a half-maximal response at 1-10
ng/ml (Fig. 2B). The OSM dose response at the level of
immediate signaling (Fig. 2B) closely correlated with the
change in renin and TIMP-1 mRNA abundance (Fig. 1E)
Endotoxin-induced Renal Inflammatory Response
ONCOSTATIN M AS A MAJOR MEDIATOR OF SUPPRESSED RENIN
EXPRESSION*
§,
,
,
, and
Department of Molecular and Cellular
Biology, Roswell Park Cancer Institute, Buffalo, New York 14263 and the
¶ Department of Pathology and Molecular Medicine, McMaster
University, Hamilton, Ontario L8N 3Z5, Canada
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
62 to +47; Ref. 10); murine Ren-1C promoter-CAT constructs, pRen-1(4.1kb)-CAT, pRen-1(3.1kb)-CAT, pRen-1(2.6kb)-CAT, pRen-1(
4.1 to
2.6kb/
117 to +6)-CAT, pRen-1(
2866 to
2625/
117 to +6)-CAT (11), pRen-1(
2699 to
2625/
117 to +6)-CAT, and pRen-1(
2699 to
2625[M2]/
117 to +6)-CAT (the predicted cAMP response element site at
2697 to
2690 mutated from TGACATCA to
TtctATCA; and pRen-1(
2866 to
2625/
364 to +6)-CAT and
pRen-1(
2866 to
2625/
696 to +6)-CAT generated by standard cloning
techniques.2 The following
expression vectors were used: rat STAT5B, dominant negative mutant
STAT5B
40C, STAT3 (12), and dominant negative mutant STAT3
55C
(13); the dominant negative A-CREB (14) and A-Fos (15) in pRc/CMV
(InVitroGen); and pEGFP-N1 (Upstate Biotechnology, Inc.).
(Immunex Corp.), TNF
(Genentech), and 10 µg/ml LPS (serotype 0127:B8; Sigma). A digital image of each GFP positive culture
was taken under an inverted fluorescence microscope (Nikon) with a SPOT
camera, and fluorescence above background for a constant view area was
quantitated in the NIH Image program version 1.62. The integrated net
pixel values served as a measure for transfection efficiency. CAT
activity in serially diluted cell extract was determined, normalized to
the GFP signal for each culture, and expressed as relative CAT
activity. Aliquots of cell extract were separated on 10%
SDS-polyacrylamide gels. Proteins were electrotransferred onto protean
membranes (Schleicher & Schuell). Membranes were reacted with primary
antibodies to phosphotyrosine (py20, Transduction Laboratories; 4G10,
Upstate Biotechnologies), STAT3 and STAT5 (Santa Cruz Biotechnology),
phosphorylation-specific anti-STAT3, STAT5, and ERK1/2 (New England
Biolabs), followed by secondary horseradish peroxidase-conjugated
antibodies (Capel) and visualized by ECL (Amersham Pharmacia Biotech).
SAA isoforms synthesized and secreted by As4.1 cells were identified by
immunoblotting using isofrom-sepcific antibodies against mouse SAA
proteins (generously provided by Dr. E. P. Benditt, University of
Washington, Seattle, WA).
1-protease inhibitor, or TIMP-1. The hybridization signals
were quantitated by PhosphorImager scanning and analysis with the
ImageQuant program (Molecular Dynamics). The digital image of the
ethidium bromide stained 28 S rRNA band served as loading marker and
was quantitated by analysis with the NIH Image program 1.62. The
hybridization signal was normalized to the 28 S rRNA signal. In each
experimental series, the mean value of the control animals was defined
as 100%, and the values of each animal were then expressed relative to that control mean values.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, TNF
, IL-6, LIF, and OSM (21-23). The second
model, the turpentine-induced sterile tissue injury model, causes a
confined but strong local inflammation and initiates a systemic acute
phase reaction by means of humoral mediators of which IL-6 is the most significant component (24).

View larger version (59K):
[in a new window]
Fig. 1.
Gene regulation in kidney (A
and B) and As4.1 cells
(C-E). A, male C57BL/6 mice, in
duplicates as indicated at the bottom, were treated for
24 h with LPS or turpentine. 20 µg of kidney and 5 µg of liver
RNA were analyzed by Northern blot hybridization for the mRNAs
listed at the right. The ethidium bromide (EtBr)
pattern of the 28 S rRNA served as loading control. Autoradiographic
exposures of the kidney RNA blots were 24-72 h, and those of the liver
RNA were for 6 h. B, compilation of the relative levels
of renin mRNA expression determined in individual mice from five
independent series (left panel) and in four separate
experiments with of As4.1 cells (right panel). Note that the
culture of untreated control As4.1 cells in each experimental series is
defined as 100%. C-E, in four separate experimental
series, As4.1 cells were treated for 24 h with serum-free medium
containing the factors listed at the bottom. RNA (20 µg)
were analyzed by Northern blot hybridization.
, and TNF
(Fig. 1,
C and D). Time course analysis indicated maximal effects on gene induction at 24 h of treatment (data not shown). OSM yielded the most prominent suppression of renin (Fig.
1B, right panel); smaller but significant
reductions were also obtained with IL-6, IL1
, and TNF
(Fig.
1C and D). LIF appeared to be essentially
ineffective (Fig. 1C). Endotoxin was also able to act
directly on As4.1 cells to reduce renin mRNA abundance (Fig. 1D). Additional specificity in cell response was noted in
the strong induction of TIMP-1 by OSM (only weakly by IL-6) and the more effective regulation of SAA by IL-1
, TNF
, and endotoxin. Analysis of As4.1 mRNA (28) and cellular and secreted proteins by
anti-SAA immunoglobulins indicated that As4.1 cells expressed only the
SAA-3 gene (data not shown). Although the expression and regulation of
renin, TIMP-1 and SAA genes in As4.1 cells mirrored responses observed
for total kidney in vivo, the As4.1 cells differed from
kidney by not expressing haptoglobin and
1-protease inhibitor.
, TNF
, or endotoxin gave distinct
patterns of gene regulation. Although all combinations were more
inhibitory on renin expression than each factor alone, only the
combination of OSM and IL-1
synergistically enhanced expression of
SAA (Fig. 1C). The other combinations showed mutually reduced action on the SAA gene (Fig. 1D). We next tested the
effects of dexamethasone in combination with cytokines on As4.1 cells, in an attempt to mimic the composition of effectors presumed to exist
during the inflammatory response after activation of the hypothalamic-adrenal axis in vivo. In As4.1 cells,
dexamethasone reduced renin expression but also attenuated
OSM-stimulation of TIMP-1 expression (Fig. 1C). The
divergent actions of OSM, i.e. suppression of renin and
induction of TIMP-1, followed the same OSM dose dependence with maximal
effect measured at 100 ng/ml (Fig. 1E). The induction of
genes in As4.1 cells exhibited identical OSM dose responses as the
induction of APP genes in hepatic
cells,3 suggesting common
signaling mechanisms.

View larger version (59K):
[in a new window]
Fig. 2.
Cytokine signaling in As4.1 cells.
A, cells were treated for 10 min with the cytokines listed
at the bottom. Whole cell lysate were analyzed by Western
blot reaction (W.B.) for tyrosine phosphorylated cellular
proteins (PY), and tyrosine phosporylated and total STAT3,
STAT5 and for phosphorylated ERK as indicated. B, As4.1
cells were treated for 10 min with increasing dose of IL-6 or OSM, and
the effects on STAT activation were determined by immunoblot
reactions.
The transcriptional effects of OSM were tested in transiently
transfected As4.1 cells (Fig.
3A). As4.1 cells supported a
minor induction of the OSM-responsive, STAT5-sensitive test construct p(8xHRRE)-CAT, whereas the 4.1-kb renin-CAT construct yielded a
prominent basal expression that was reduced by OSM and other effectors.
The relative rank order of activities in the transfection reporter
assay were comparable with those detected at the level of renin
mRNA abundance (Fig. 3A versus Fig. 1,
C and D). The profile of regulation for the
transfected TIMP-1 promoter contrasted sharply with that observed for
the renin promoter, and the robust induction of the TIMP-1-CAT
construct by OSM was in accordance with regulation of the endogenous
TIMP-1 gene. A strong contributing activity of OSM-activated STAT
proteins was suggested.
|
The prominent cell type-specific expression of the 4.1-kb renin-CAT
construct has been described to depend on two critical elements: a
promoter proximal element at position
60 and a distal enhancer
element (DEE) at position
2690 (11). A set of promoter truncations
and mutations was tested to localize the functional element(s)
responsible for OSM suppression (Fig. 3B). With deletion of
the DEE, essentially all expression was abolished. Removal of the
intervening sequence between DEE and position
117 reduced the basal
expression of the promoter less than 2-fold but eliminated suppression
by OSM. The mutation of a cAMP response element modulator/CREB-binding element within the DEE reduced basal expression but did not reintroduce either positive or negative responsiveness to OSM. By retaining more 5'
flanking sequence upstream of
117, the region from
694 to
365 was
found to restore full sensitivity to OSM inhibition of promoter
activity. This region contains at
650 a negative regulatory element
(NRE) that has been suggested to exert an inhibitory activity on
constitutive expression of the renin gene (29).
To identify signaling molecules that potentially connect the OSMR to
the renin gene regulatory element, we assessed the relative contribution of the particularly strong activated ERK and STAT pathways
(Fig. 2A). Inhibition of MEK-1 by U0126 during OSM treatment did not affect OSM inhibition (Fig.
4A). Dominant negative A-Fos was unable to modify promoter activity. In contrast, the dominant negative A-CREB essentially abolished all promoter activity, likely through neutralization of the DEE-interacting cAMP response element modulator/CREB proteins.2 Overexpression of the dominant
negative STAT3
55C was inconsequential; however, the dominant
negative STAT5B
40C severely reduced basal expression, as well as
expression in OSM-treated cells (Fig. 4A). The inhibition by
STAT5B
40C in the absence of OSM treatment probably reflected the
elevated DNA binding activity of STAT5 proteins as a result of
overexpression (30). The same inhibitors and dominant negative
transcription factors were used to characterize the regulation of the
TIMP-1-CAT reporter gene construct. A fundamentally different, inverse
pattern of action was observed. In this case, U0126 inhibition of MEK
lowered the OSM-dependent OSM induction. Similarly, A-Fos,
the dominant forms for STAT3 and STAT5 reduced TIMP-1-CAT expression
(Fig. 4B).
|
To determine whether the probable mode of STAT5B
40C inhibition of
renin promoter activity was mediated via the NRE-containing region,
different length promoter proximal 5'-flanking regions linked to the
DEE were challenged by OSM treatment in the presence of overexpressed
STAT5B
40C (Fig. 4C). Significant suppression was evident
for the
696 promoter construct, which included the NRE. The
suppression of basal and OSM-induced inhibition by truncated STAT5
suggest that interaction of STAT5 either directly with the DNA site or
indirectly through an the NRE-associated component is sufficient to
obtain inhibition. That STAT5B, with or without the C-terminal
transactivation domain, could act as an inhibitor was confirmed by
demonstrating that suppression of renin promoter activity by
overexpressed wild type STAT5B occurred to the same extent as observed
for truncated STAT5B (Fig. 4C).
The combined results from the tissue culture analyses strongly support
a prominent renin suppressing activity of OSM that in part could
account for the effects observed in kidneys of LPS-treated mice (Fig.
1, A and B, left panel). To directly
assess an inhibitory activity of OSM in vivo, we next
determined renin mRNA levels in the kidneys of mice infected with
an adenoviral vector expressing murine OSM (Fig.
5). Whereas the animals infected with
control virus did not show appreciable changes in APP expression, the AdmOSM-treated animals demonstrated within 48 h an enhanced level of liver APP mRNA and serum APP levels that were characteristic for
OSM and a prominent reduction of renin mRNA in the kidney. Taken
together, these data support the notion that endotoxin action in
kidney, presumably by resident macrophages, may involve the local
production of OSM, which, together with other inflammatory cytokines
and endotoxin, suppresses renin expression in juxtaglomerular cells
in vivo by mechanisms comparable with that observed for As4.1 cells in vitro.
|
| |
DISCUSSION |
|---|
|
|
|---|
The inflammation-specific reduction of renin expression identifies this gene product as a potential negative acute phase reactant. Although secretion of renin, a regulated process in juxtaglomerular cells, may not precisely track the kinetics of the acute phase-induced reduction observed for renin mRNA levels during the chronic stage of inflammatory reaction, a decrease in the RPC is expected that likely will assume physiologically relevant consequences for blood pressure homeostasis.
At issue in this study is the cell type-specific regulation of APP production and the relative role of specific inflammatory cytokines. Although the hepatic induction of APP genes and the synthesis of their cognate products clearly represents a dominant process systemically, the availability or accumulation of the individual plasma proteins in physiologically significant levels at distant sites of inflammation may require on the order several hours to occur. An alternative mechanism to gain protective APPs at sites of inflammation has been suggested to occur through local production. Extrahepatic APP synthesis has been noted in organs such as lung and intestine that are especially exposed to insults (31). Our data indicate that kidney possesses a capability to carry out a similar process that involves positively and negatively affected genes. The response of As4.1 cells suggests that the positive APPs comprise a cellular response for juxtaglomerular cells in situ that is similar to that identified for interstitial myofibroblasts and mediated by the same signal transduction systems as the inhibition of renin (32).
The primary regulators of positive as well as negative APP have emerged
as IL-1- and IL-6-type cytokines. Increased transcription of various
APP genes is attributable to the action of specific sets of
transcription factors that generally include CCAAT/enhancer-binding protein
and nuclear factor
B, stimulated primarily by IL-1 cytokines, and STAT3 and AP-1 components, stimulated by IL-6 cytokines. The mode of regulation of negative APPs is less well understood but
appears to involve in part the same transcription factors as those
acting on positive APP genes (33).
The contrasting regulatory action of OSM on renin versus
TIMP-1 gene expression in As4.1 cells revealed a novel mechanism. Although transcriptional activity of the renin gene appears to be
moderated by a number of proinflammatory cytokines and dexamethasone (Fig. 1), the signaling through OSMR emerged as particularly effective. The identification of STAT5 as an inhibitor of renin gene expression explains in part the OSM effect, as OSMR signaling, unlike that of the
other IL-6 cytokine receptors, involves STAT5 as a major signal-transducing component. The observation that other effectors, such as LPS, IL-1
, TNF
, and dexamethasone, and even to some extent IL-6, all of which are not associated with prominent STAT5 activation, can also reduce renin expression implies that STAT5 is not
the exclusive suppressor of renin but that additional pathways act on
renin gene expression. The identity of those intracellular mediators
and their genetic targets within the renin gene remain to be established.
STAT5 has been recognized to be a preferred substrate for activation by several hematopoietin receptors and generally been associated with stimulated transcription (34). The inhibition of renin by STAT5 involves a mode of action that appears to be distinct from its stimulatory functions. Moreover, although there is a clear requirement for specific promoter elements, the suppression effect is manifested irrespectively of the presence of the transactivating domain on STAT5. Precedent for such an inhibitory activity has been reported recently for STAT5 in regulation of the IRF-1 promoter by prolactin (35). We have been unable to identify a STAT5-binding element in the renin promoter or to detect a direct physical interaction of activated STAT5B with the region containing the NRE.4 Conceivably, STAT5 may bind to DNA recognition sequences, but that interaction is undetectable by the in vitro assay conditions employed, or STAT5 may be acting indirectly through association with other transcription factors (squelching). In either case, we would expect that STAT5 exerts its transcriptional suppression by interfering with the strong transcriptional regulators of the renin gene.
Our results demonstrate the regulatory capability of the kidney in
response to an acute inflammatory process. Preliminary results with
animals treated repeatedly with LPS for several days indicate a
persistent expression patterns of enhanced APPs and reduced
renin.4 Yet to be determined is the influence of
inflammatory stimuli, which are expected to be present during chronic
renal inflammatory diseases. Long term intrarenal tissue damage,
coupled with inflammatory cell activities, would inevitably introduce
new conditions that will affect the regulatory phenotype of the kidney.
This will include not only an adaptive regulation of the
renin/angiotensin system but also a profound tissue repair reaction
that results in a change in tissue composition, as best exemplified by
interstitial fibrosis (32, 36).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Immunex Corp. and the Genetics Institute for providing recombinant cytokines, Dr. F. L. Graham for control adenovirus, Dr. W. Liao for mouse SAA-1 cDNA, Dr. P. Soloway for TIMP-1 cDNA, Dr. Benditt for SAA antisera, and Colleen Kane-Haas, Erin Kinzie, and colleagues at the laboratory animal facility for technical assistance.
| |
FOOTNOTES |
|---|
* This work was supported in part by National Institutes of Health Grants DK33886 (to H. B.) and HL48459 (to K. W. G.), by funds from the Arthritis Society of Canada (to C. D. R.), and Roswell Park Cancer Institute Support Grant CA16056.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Dept. of Molecular and Cellular Biology, Roswell Park Cancer Inst., Elm and Carlton Sts., Buffalo, NY 14263. Tel.: 716-845-4587; Fax: 716-845-8389; E-mail: Heinz.Baumann@sc3101.med.buffalo.edu.
Published, JBC Papers in Press, May 9, 2000, DOI 10.1074/jbc.M002830200
2 T. A. Black, S. A. Ou, Q. Shi, C. A. Jones, L. Pan, C. Kane, N. Petrovic, J. Loudon, C. D. Sigmund, and K. W. Gross, submitted for publication.
3 Y. Wang, O. Robledo, E. Kinzie, F. Blanchard, C. D. Richards, A. Miyajima, and H. Baumann, submitted for publication.
4 H. Baumann, Y. Wang, C. D. Richards, C. A. Jones, T. A. Black, and K. W. Gross, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: APP, acute phase protein; CREB, cAMP response element-binding protein; DEE, distal enhancer element; GFP, green fluorescent protein; IL, interleukin; LIF, leukemia inhibitory factor; LPS, lipopolysaccharide; NRE, negative regulatory element; OSM, oncostatin M; SAA, serum amyloid A; STAT, signal transducer and activator of transcription; TIMP-1, tissue inhibitor for metalloproteinase-1; CAT, chloramphenicol acetyltransferase; TNF, tumor necrosis factor; kb, kilobase(s).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Gabay, C., and Kushner, I. (1999) N. Engl. J. Med. 340, 448-454 |
| 2. | Titheradge, M. A (1999) Biochim. Biophys. Acta 1411, 437-455 |
| 3. | Mashimo, H., and Goyal, R. K. (1999) Am. J. Physiol. 277, G745-G750 |
| 4. | Kageyama, R., Ohkubo, H., and Nakanishi, S. (1985) Biochem. Biophys. Res. Commun. 129, 826-832 |
| 5. | Okamoto, H., Hatta, A., Itoh, N., Ohashi, Y., Arakawa, K., and Nakanishi, S. (1987) Biochem. Pharmacol. 36, 3069-3074 |
| 6. | Okamoto, H., Ohashi, Y., and Itoh, N. (1987) Biochem. Biophys. Res. Commun. 145, 1225-1230 |
| 7. | Wernze, H., and Weiss, H. (1979) Horm. Metab. Res. 11, 371-374 |
| 8. | Ohtani, R., Ohashi, Y., Muranaga, K., Ithoh, N., and Okamoto, H. (1989) Life Sci. 44, 237-241 |
| 9. | Morella, K. K., Lai, C., Kumaki, S., Kumaki, N., Wang, Y., Bluman, E. M., Witthuhn, B. A., Ihle, J. N., Giri, J., Gearing, D. P., Cosman, D., Ziegler, S. F., Tweardy, D. J., Campos, S. P., and Baumann, H. (1995) J. Biol. Chem. 270, 8298-8310 |
| 10. | Botelho, F. M., Edwards, D. R., and Richards, C. D. (1998) J. Biol. Chem. 273, 5211-5218 |
| 11. | Petrovic, N., Black, T. A., Fabian, J. R., Kane, C., Jones, C. A., Loudon, J. A., Abonia, J. P., Sigmund, C. D., and Gross, K. W. (1996) J. Biol. Chem. 271, 22499-22505 |
| 12. | Ripperger, J., Fritz, S., Richter, K., Hocke, G. M., Lottspeich, F., and Fey, G. H. (1995) J. Biol. Chem. 270, 29998-30006 |
| 13. | Kim, H., and Baumann, H. (1997) J. Biol. Chem. 272, 14571-14579 |
| 14. | Ahn, S., Olive, M., Aggarwal, S., Krylov, D., Ginty, D. D., and Vinson, C. (1998) Mol. Cell. Biol. 18, 967-977 |
| 15. | Olive, M., Krylov, D., Echlin, D. R., Gardner, K., Taparowsky, E., and Vinson, C (1997) J. Biol. Chem. 272, 18586-18549 |
| 16. | Tanaka, M., Hara, T., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Miyajima, A (1999) Blood 93, 804-815 |
| 17. | Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8802-8806 |
| 18. | Kerr, C., Langdon, C., Graham, F., Gauldie, J., Hara, T., and Richards, C. D. (1999) J. Interf. Cyt. Res. 19, 1195-1205 |
| 19. | Karima, R., Matusmoto, S., Higashi, H., and Matsushima, K. (1999) Mol. Med. Today 5, 123-132 |
| 20. | Wiese, A, Brandenburg, K., Ulmer, A. J., Seydel, U., and Muller-Loennies, S. (1999) Biol. Chem. 380, 767-784 |
| 21. | Matsukawa, A., and Yoshinaga, M. (1998) Inflamm. Res. 47, S137-S144 |
| 22. | Yoshimura, A., Ichihara, M., Kinjyo, I., Moriyama, M., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Hara, T., and Miyajima, A. (1996) EMBO J. 15, 1055-1063 |
| 23. | Grenier, A., Dehoux, M., Boutten, A., Arce-Vicioso, M., Durand, G., Gougerot-Pocidalo, M. A., and Chollet-Martin, S. (1999) Blood 93, 1413-1421 |
| 24. | Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., and Kohler, G. (1994) Nature 368, 339-342 |
| 25. | Kaibara, A., Espar, N. J., Auffenberg, T., Abouhamze, A. S., Martin, D., Kalra, S., and Moldawer, L. L. (1998) Cytokine 10, 452-456 |
| 26. | Naemura, J. R., and Radka, S. F. (1993) Lymphokine Cytok. Res. 12, 187-190 |
| 27. | Sigmund, C. D., Okuyama, K., Ingelfinger, J., Jones, C. A., Mullins, J. J., Kane, C., Kim, U., Wu, C. Z., Kenny, L., Rustum, Y., and Gross, K. W. (1990) J. Biol. Chem. 265, 19916-19922 |
| 28. | Thompson, H. A., Burson, J. M., Lang, J. A., Gross, K. W., and Sigmund, C. D. (1995) Endocrinology 136, 3037-3045 |
| 29. | Yamada, T., Horiuchi, M., Morishita, R., Zhang, L., Pratt, R. E., and Dzau, V. J. (1995) J. Clin. Invest. 96, 1230-1237 |
| 30. | Schaefer, T. S., Sanders, L. K., and Nathans, D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 13704-13708 |
| 31. | Schreiber, G., and Aldred, A. R. (1993) in Acute Phase Proteins, Molecular Biology, Biochmistry, and Clinical Applications (Mackiewicy, A. , Kushner, I. , and Baumann, H., eds) , pp. 39-76, CRC Press, Boca Raton, FL |
| 32. | Duymelinck, C., Deng, J.-T., Dauwe, S. E. H., De Broe, M. E., and Verpooten, G. A. (1998) Kidney Int. 54, 804-818 |
| 33. | Qian, X., Samadani, U., Porcella, A., and Costa, R. H. (1995) Mol. Cell. Biol. 15, 1364-1376 |
| 34. | Ihle, J. N. (1996) Cell 84, 331-334 |
| 35. | Luo, G., and Yu-Lee, L. (1997) J. Biol. Chem. 272, 26841-26846 |
| 36. | Lopez-Novoa, J. M. (1999) Kid. Intern. 55, 1672-1682 |
This article has been cited by other articles:
![]() |
X. Zhou, E. T. Weatherford, X. Liu, E. Born, H. L. Keen, and C. D. Sigmund Dysregulated human renin expression in transgenic mice carrying truncated genomic constructs: evidence supporting the presence of insulators at the renin locus Am J Physiol Renal Physiol, September 1, 2008; 295(3): F642 - F653. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhou and C. D. Sigmund Chorionic enhancer is dispensable for regulated expression of the human renin gene Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R279 - R287. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Itani, X. Liu, J. H. Pratt, and C. D. Sigmund Functional Characterization of Polymorphisms in the Kidney Enhancer of the Human Renin Gene Endocrinology, March 1, 2007; 148(3): 1424 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, Q. Shi, and C. D. Sigmund Interleukin-1{beta} Attenuates Renin Gene Expression Via a Mitogen-Activated Protein Kinase Kinase-Extracellular Signal-Regulated Kinase and Signal Transducer and Activator of Transcription 3-Dependent Mechanism in As4.1 Cells Endocrinology, December 1, 2006; 147(12): 6011 - 6018. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhoux, D. R. Davis, and C. D. Sigmund The Human Renin Kidney Enhancer Is Required to Maintain Base-line Renin Expression but Is Dispensable for Tissue-specific, Cell-specific, and Regulated Expression J. Biol. Chem., November 17, 2006; 281(46): 35296 - 35304. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. T. Todorov, S. Volkl, J. Friedrich, L. A. Kunz-Schughart, T. Hehlgans, L. Vermeulen, G. Haegeman, M. L. Schmitz, and A. Kurtz Role of CREB1 and NF{kappa}B-p65 in the Down-regulation of Renin Gene Expression by Tumor Necrosis Factor {alpha} J. Biol. Chem., July 1, 2005; 280(26): 24356 - 24362. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pan, Y. Wang, C. A. Jones, S. T. Glenn, H. Baumann, and K. W. Gross Enhancer-dependent inhibition of mouse renin transcription by inflammatory cytokines Am J Physiol Renal Physiol, January 1, 2005; 288(1): F117 - F124. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pan and K. W. Gross Transcriptional Regulation of Renin: An Update Hypertension, January 1, 2005; 45(1): 3 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. T. Todorov, S. Volkl, M. Muller, A. Bohla, J. Klar, L. A. Kunz-Schughart, T. Hehlgans, and A. Kurtz Tumor Necrosis Factor-{alpha} Activates NF{kappa}B to Inhibit Renin Transcription by Targeting cAMP-responsive Element J. Biol. Chem., January 9, 2004; 279(2): 1458 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Persson, A. Skalweit, R. Mrowka, and B.-J. Thiele Control of renin synthesis Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R491 - R497. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Todorov, M. Muller, F. Schweda, and A. Kurtz Tumor necrosis factor-alpha inhibits renin gene expression Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1046 - R1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Repovic and E. N. Benveniste Prostaglandin E2 Is a Novel Inducer of Oncostatin-M Expression in Macrophages and Microglia J. Neurosci., July 1, 2002; 22(13): 5334 - 5343. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE |